C07C 233/59
Having the nitrogen atom of at least one of the carboxamide groups
Official title: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
C07C233/59 (Having the nitrogen atom of at least one of the carboxamide groups) appears on 73 US grants and 88 published applications in this corpus.
Search patents in C07C- Granted patents
- 73
- Published applications
- 88
- Assignees
- 51
- Inventors
- 307
- Latest grant
- 7 Oct 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 4 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 3 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 3 |
| 2004 | 1 | 4 |
| 2005 | 1 | 5 |
| 2006 | 1 | 2 |
| 2007 | 3 | 3 |
| 2008 | 3 | 1 |
| 2009 | 0 | 1 |
| 2010 | 2 | 1 |
| 2011 | 3 | 1 |
| 2012 | 1 | 8 |
| 2013 | 3 | 0 |
| 2014 | 5 | 12 |
| 2015 | 5 | 3 |
| 2016 | 5 | 10 |
| 2017 | 7 | 10 |
| 2018 | 2 | 6 |
| 2019 | 1 | 0 |
| 2020 | 5 | 1 |
| 2021 | 0 | 2 |
| 2022 | 2 | 2 |
| 2023 | 1 | 1 |
| 2024 | 3 | 7 |
| 2025 | 1 | 2 |
| 2026 | 0 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof7 Oct 2025US 12,435,051 B2Vivozon Inc.
- Compounds and methods for liquid phase oligonucleotide synthesis31 Dec 2024US 12,180,140 B2Hongene Biotech Corporation
- Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof13 Aug 2024US 12,060,339 B2Vivozon Inc.
- Sphingosine kinase inhibitors23 Jan 2024US RE49,811 E1Apogee Biotechnology Corporation
- Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection10 Jan 2023US 11,548,893 B2Arisan Therapeutics Inc.
- Resist composition, resist pattern formation method, compound, and acid diffusion control agent16 Jul 2026US 2026/0202743 A1Tokyo Ohka Kogyo.Co., Ltd.
- Cycloalkyl carboxylic acid derivatives as inhibitors of glycogen synthase 1 (gys1) and methods of use thereof22 Jan 2026US 2026/0021085 A1Maze Therapeutics, Inc.
- Chemical compounds and uses thereof15 Jan 2026US 2026/0015321 A1Glaxosmithkline Intellectual Property (No. 4) Ltd.
- Compounds and methods for liquid phase oligonucleotide synthesis16 Oct 2025US 2025/0320177 A1Hongene Biotech Corporation
- Allosteric modulators of nicotinic acetylcholine receptors2 Jan 2025US 2025/0002448 A1Merck Sharp & Dohme Corp.
Most cited
By later US patents
- Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method125US 5,760,246 A1998
- N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)69US 5,656,634 APfizer Inc. · 1997
- Method of preparing substituted malonic ester anilides and malonic acid mono-anilides59US 5,334,747 AHuls Aktiengesellschaft · 1994
- Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)49US 5,362,878 APfizer Inc. · 1994
- Process for preparing quinoline derivatives27US 9,365,516 B2Exelixis, Inc. · 2016